Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: a potential new therapeutic approach
- PMID: 24678876
- PMCID: PMC3972996
- DOI: 10.1186/1471-2407-14-230
Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: a potential new therapeutic approach
Abstract
Background: Approximately 30% of breast tumors do not express the estrogen receptor (ER) α, which is necessary for endocrine therapy approaches. Studies are ongoing in order to restore ERα expression in ERα-negative breast cancer. The aim of the present study was to determine if calcitriol induces ERα expression in ER-negative breast cancer cells, thus restoring antiestrogen responses.
Methods: Cultured cells derived from ERα-negative breast tumors and an ERα-negative breast cancer cell line (SUM-229PE) were treated with calcitriol and ERα expression was assessed by real time PCR and western blots. The ERα functionality was evaluated by prolactin gene expression analysis. In addition, the effects of antiestrogens were assessed by growth assay using the XTT method. Gene expression of cyclin D1 (CCND1), and Ether-à-go-go 1 (EAG1) was also evaluated in cells treated with calcitriol alone or in combination with estradiol or ICI-182,780. Statistical analyses were determined by one-way ANOVA.
Results: Calcitriol was able to induce the expression of a functional ERα in ER-negative breast cancer cells. This effect was mediated through the vitamin D receptor (VDR), since it was abrogated by a VDR antagonist. Interestingly, the calcitriol-induced ERα restored the response to antiestrogens by inhibiting cell proliferation. In addition, calcitriol-treated cells in the presence of ICI-182,780 resulted in a significant reduction of two important cell proliferation regulators CCND1 and EAG1.
Conclusions: Calcitriol induced the expression of ERα and restored the response to antiestrogens in ERα-negative breast cancer cells. The combined treatment with calcitriol and antiestrogens could represent a new therapeutic strategy in ERα-negative breast cancer patients.
Figures







Similar articles
-
Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An Update.Int J Mol Sci. 2021 Nov 25;22(23):12741. doi: 10.3390/ijms222312741. Int J Mol Sci. 2021. PMID: 34884550 Free PMC article. Review.
-
The vitamin D analog EB1089 sensitizes triple-negative breast cancer cells to the antiproliferative effects of antiestrogens.Adv Med Sci. 2024 Sep;69(2):398-406. doi: 10.1016/j.advms.2024.08.004. Epub 2024 Sep 2. Adv Med Sci. 2024. PMID: 39233278
-
EB1089 Increases the Antiproliferative Response of Lapatinib in Combination with Antiestrogens in HER2-Positive Breast Cancer Cells.Int J Mol Sci. 2024 Mar 9;25(6):3165. doi: 10.3390/ijms25063165. Int J Mol Sci. 2024. PMID: 38542136 Free PMC article.
-
Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.Mol Cancer Ther. 2008 Jul;7(7):2096-108. doi: 10.1158/1535-7163.MCT-07-2350. Mol Cancer Ther. 2008. PMID: 18645020 Free PMC article.
-
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.Oncogene. 2003 Oct 20;22(47):7316-39. doi: 10.1038/sj.onc.1206937. Oncogene. 2003. PMID: 14576841 Review.
Cited by
-
Vitamin D: an essential adjuvant therapeutic agent in breast cancer.J Int Med Res. 2022 Jul;50(7):3000605221113800. doi: 10.1177/03000605221113800. J Int Med Res. 2022. PMID: 35883275 Free PMC article. Review.
-
Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An Update.Int J Mol Sci. 2021 Nov 25;22(23):12741. doi: 10.3390/ijms222312741. Int J Mol Sci. 2021. PMID: 34884550 Free PMC article. Review.
-
BC-N102 suppress breast cancer tumorigenesis by interfering with cell cycle regulatory proteins and hormonal signaling, and induction of time-course arrest of cell cycle at G1/G0 phase.Int J Biol Sci. 2021 Jul 25;17(12):3224-3238. doi: 10.7150/ijbs.62808. eCollection 2021. Int J Biol Sci. 2021. PMID: 34421361 Free PMC article.
-
Inhibitors for the Vitamin D Receptor-Coregulator Interaction.Vitam Horm. 2016;100:45-82. doi: 10.1016/bs.vh.2015.10.002. Epub 2015 Nov 30. Vitam Horm. 2016. PMID: 26827948 Free PMC article. Review.
-
PRIMA-1MET Does Not Restore Vitamin D Sensitivity to MDA-MB-231 and MDA-MB-468 Triple-Negative Breast Cancer Cells.ACS Omega. 2023 Aug 8;8(33):30500-30507. doi: 10.1021/acsomega.3c03719. eCollection 2023 Aug 22. ACS Omega. 2023. PMID: 37636961 Free PMC article.
References
-
- Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–10874. doi: 10.1073/pnas.191367098. - DOI - PMC - PubMed
-
- Clark GM, McGuire WL. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol. 1988;15(2 Suppl 1):20–25. - PubMed
-
- McGuire WL, Osborne CK, Clark GM, Knight WA 3rd. Steroid hormone receptors and carcinoma of the breast. Am J Physiol. 1982;243(2):E99–E102. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous